CASTLE BIOSCIENCES INC (CSTL)

24.15 0 (0%)

As of 2025-10-28 15:29:10 EST

DecisionDx-UM is a prognostic test that accurately determines the metastatic risk associated with ocular melanoma tumors of the eye. Ocular melanoma is a term commonly used to describe tumors of the uveal tract such as uveal melanoma, choroidal melanoma, ciliary body melanoma, and iris melanoma. The DecisionDx-UM test was clinically validated on these tumors of the uveal tract. DecisionDx-UM assesses the gene expression profile (GEP) of a subset of genes which are differentially expressed in primary tumor cells compared to cells that have undergone transformation to a metastatic phenotype.

Traded asNasdaq: CSTL
ISINUS14843C1053
CIK0001447362
LEI2549007M2Q4HLR1XD252
EIN770701774
Sector—
IndustryServices-Medical Laboratories
CEO—
Employees—
Fiscal Year End1231
Address505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX, 77546
Phone866-788-9007
Website—
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
CSTLCASTLE BIOSCIENCES INC2025-10-28 15:29:1024.1500
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
CSTL0001447362CASTLE BIOSCIENCES INCUS14843C10532549007M2Q4HLR1XD252770701774Nasdaq8071Services-Medical Laboratories1231DE505 S FRIENDSWOOD DRIVEFRIENDSWOODTX77546UNITED STATESUS866-788-9007505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX, 77546505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX, 77546——————587,000,00028,981,15129,008,281DecisionDx-UM is a prognostic test that accurately determines the metastatic risk associated with ocular melanoma tumors of the eye. Ocular melanoma is a term commonly used to describe tumors of the uveal tract such as uveal melanoma, choroidal melanoma, ciliary body melanoma, and iris melanoma. The DecisionDx-UM test was clinically validated on these tumors of the uveal tract. DecisionDx-UM assesses the gene expression profile (GEP) of a subset of genes which are differentially expressed in primary tumor cells compared to cells that have undergone transformation to a metastatic phenotype.2025-10-23 14:45:20
This is a preview of the latest data. Subscribe to access the full data.
CSTL Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
CSTL Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024587,000,000276,000,00088.74628,514,1091,064,1263.8766
2023311,000,000-161,000,000-34.110227,449,983874,3673.2901
2022472,000,000-1,028,000,000-68.533326,575,6161,165,0144.5848
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Kristen M. OelschlagerChief Operating Officer2024506,41513,9261,563,738342,70120,1502,446,931
Tobin W. JuvenalChief Commercial Officer2024506,41513,9261,563,738342,70120,1502,446,931
Derek J. MaetzoldCEO, President2024715,57205,283,595921,65720,2506,941,074
Kristen M. OelschlagerChief Operating Officer2023482,3009,6460312,53024,008828,484
Frank StokesChief Financial Officer2023488,8004,8880316,74269,820880,250
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024761
2023610
2022543
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue332,069,000219,788,000137,039,000
Cost Of Revenue60,205,00044,982,00032,009,000
Gross Profit———
Research And Development Expenses52,041,00053,618,00044,903,000
General And Administrative Expenses200,047,000180,152,000143,003,000
Operating Expenses323,399,000287,765,000209,894,000
Operating Income8,670,000-67,977,000-72,855,000
Net Income18,245,000-57,466,000-67,138,000
Earnings Per Share Basic0.66-2.14-2.58
Earnings Per Share Diluted0.62-2.14-2.58
Weighted Average Shares Outstanding Basic27,776,00026,802,00026,054,000
Weighted Average Shares Outstanding Diluted29,255,00026,802,00026,054,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents119,709,00098,841,000122,948,000
Marketable Securities Current173,421,000144,258,000135,677,000
Accounts Receivable51,218,00038,302,00023,476,000
Inventories8,135,0007,942,0003,980,000
Non Trade Receivables———
Other Assets Current———
Total Assets Current360,154,000295,635,000292,288,000
Marketable Securities Non Current———
Property Plant And Equipment——14,315,000
Other Assets Non Current1,228,0001,440,0001,110,000
Total Assets Non Current171,081,000157,705,000155,041,000
Total Assets531,235,000453,340,000447,329,000
Accounts Payable6,901,00010,268,0004,731,000
Deferred Revenue———
Short Term Debt278,000——
Other Liabilities Current1,076,000——
Total Liabilities Current49,392,00047,667,00036,128,000
Long Term Debt10,023,000——
Other Liabilities Non Current—25,00090,000
Total Liabilities Non Current26,008,00014,404,00012,051,000
Total Liabilities75,400,00062,071,00048,179,000
Common Stock28,00027,00027,000
Retained Earnings-200,126,000-218,371,000-160,905,000
Accumulated Other Comprehensive Income230,000136,000-381,000
Total Shareholders Equity455,835,000391,269,000399,150,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization15,997,00012,330,00010,543,000
Share Based Compensation Expense50,320,00051,219,00036,321,000
Other Non Cash Income Expense-268,000-635,000-158,000
Change In Accounts Receivable12,643,00014,930,0006,218,000
Change In Inventories193,0003,962,0001,680,000
Change In Non Trade Receivables———
Change In Other Assets-262,000330,000-618,000
Change In Accounts Payable-4,372,0005,707,000582,000
Change In Other Liabilities——0
Cash From Operating Activities64,866,000-5,626,000-41,655,000
Purchases Of Marketable Securities205,729,000189,075,000134,689,000
Sales Of Marketable Securities183,900,000186,500,000—
Acquisition Of Property Plant And Equipment28,326,00013,621,0005,632,000
Acquisition Of Business0026,966,000
Other Investing Activities———
Cash From Investing Activities-50,137,000-16,183,000-166,545,000
Tax Withholding For Share Based Compensation8,762,0005,134,0001,688,000
Payments Of Dividends———
Issuance Of Common Stock2,981,0002,709,0002,492,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt0——
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities6,139,000-2,298,0001,515,000
Change In Cash20,868,000-24,107,000-206,685,000
Cash At End Of Period119,709,00098,841,000122,948,000
Income Taxes Paid2,503,000198,000120,000
Interest Paid434,00011,00016,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share0.66-2.14-2.58
Price To Earnings Ratio40.3788-10.0841-9.124
Earnings Growth Rate-130.8411-17.0543108.0645
Price Earnings To Growth Ratio-0.30860.5913-0.0844
Book Value Per Share16.411114.598515.3201
Price To Book Ratio1.62391.47821.5365
Ebitda37,445,000-44,927,000-56,458,000
Enterprise Value630,822,400——
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.0226——
Capital Expenditures———
Free Cash Flow———
Return On Equity0.04-0.1469-0.1682
One Year Beta1.37851.68541.9333
Three Year Beta1.78521.91361.1173
Five Year Beta1.17841.1321.0837
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer2025-10-201,339D62,988
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer2025-10-021,339D64,327
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer2025-09-171,339D65,666
MAETZOLD DEREK JDirector, Pres. & Chief Exec. Officer2025-09-021,339D67,005
Oelschlager Kristen MChief Operating Officer2025-08-2718,007D153,793
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Josh Gottheimer2022-04-17NJ05Sale (Partial)2022-03-15Joint$1,001 - $15,000
Josh Gottheimer2021-01-07NJ05Purchase2020-12-21Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Campbell & CO Investment Adviser LLC2025-09-30614,69926,99622.77
Wilmington Savings Fund Society, FSB2025-09-308203622.7778
STEPHENS INC /AR/2025-09-30253,24811,12222.77
Versant Capital Management, Inc2025-09-304,12118122.768
FIRST HORIZON CORP2025-09-3010,17844722.7696
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Fidelity Rutland Square Trust II2025-08-31Strategic Advisers U.S. Total Stock FundFSAKX713,61817,133,968.180.0209
FIDELITY CONCORD STREET TRUST2025-08-31Fidelity Series Total Market Index FundFCFMX40,168964,433.680.0011
FIDELITY CONCORD STREET TRUST2025-08-31Fidelity Total Market Index FundFSKAX52,7741,267,103.740.0011
FIDELITY CONCORD STREET TRUST2025-08-31Fidelity Nasdaq Composite Index FundFNCMX13,897333,666.970.0016
FIDELITY CONCORD STREET TRUST2025-08-31Fidelity Extended Market Index FundFSMAX157,1683,773,603.680.0092
This is a preview of the latest data. Subscribe to access the full data.